Alliance First Drill Hole Completed — Shows All the Characteristics of Gold Mineralization — Bissett Gold Camp, Manitoba
Alliance Mining Corp. (TSX-v: ALM) (“Alliance” or the “Company”) is providing an update on its drill program on its Packsack gold property which began on March 15th 2018, and is being supervised by Alliance’s consulting geologist William C. Hood P. Geo. The Packsack property forms part of the company’s Red Rice Lake gold project located in Bissett Manitoba.
The first hole of the approximately 1,000 metre drill program was drilled to a depth of 380 metres under the existing Packsack shaft. Drilling under the Packsack shaft has shown that shearing, late dikes, and quartz veining with sericite, pyrite and tourmaline extend well below the 150 metre level drift. The features and mineralization observed in the core “show all the characteristics of gold mineralization found in the Packsack veins and elsewhere in the Bissett Gold camp,” says Bill Hood, P.Geo.
To view the graphic in its original size, please click here
The second drill hole in now underway. This is the first significant drill program to test under the 500 ft (152 m) level exploration drift on the Packsack property.
The Packsack property hosts several gold-bearing veins within a conjugate fracture set adjacent to the Red Rice shear zone. Previous exploration on the Packsack property has been focused on the Big Dome Vein, with a shaft to 525 ft (160 m) and 2867 ft (874 m) of drifting and crosscutting on 4 levels down to 500 ft (152 m), all completed between 1936 and 1940. The structural control on veining at the Packsack property is similar to that at the True North Mine, 4 km northeast, operated by Klondex Mines Ltd.
To view the graphic in its original size, please click here
Alliance Mining has an option to acquire 100 per cent of the Red Rice Lake property located in the centre of the Bissett gold camp in Manitoba. The property is located close to the town of Bissett, Man., and just four kilometres south from Klondex Mines’ True North gold mine. The Red Rice Lake gold property claims are located within the Archean Rice Lake greenstone belt in southeastern Manitoba. This belt forms part of the Uchi sub province that includes the Red Lake and Pickle Lake belts in Northwestern Ontario.
Alliance is actively seeking to expand its presence in the Bissett Gold camp through future property acquisitions and/or potential joint venture exploration partnerships with neighbouring companies.
William C. Hood, P.Geo, a qualified person as defined by National Instrument 43-101, is responsible for the technical information contained in this news release.
To view the graphic in its original size, please click here
ON BEHALF OF THE BOARD
Christopher R. Anderson
President, CEO and Director
FOR FURTHER INFORMATION PLEASE CONTACT:
Alliance Mining Corp.
(604) 488-3900
Investor Relations:
Antony Claydon: 604-445-5421
E-mail: ir@alliancemining.com
This press release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address future exploration drilling, exploration activities and events or developments that the Company expects, are forward looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include exploitation and exploration successes, continued availability of financing, and general economic, market or business conditions.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Alliance Mining Corp.
888 Dunsmuir Street – Suite 888, Vancouver, B.C., V6C 3K4
To view the original release (with media), please click here
Source: Alliance Mining Corp. (TSX Venture:ALM)
InvestmentPitch Media has produced a “video” which describes this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Alliance Mining” in the search box.
Cannot view this video? Visit:
http://www.investmentpitch.com/video/0_r3j2tc1w/Alliance-Mining-Corp-TSXVALM-Drill-program-Update-on-the-Packsack-Gold-Property
To follow Alliance Mining Corp. on your favorite social media platform or financial websites, please click on the icons below.
- Published in Alliance Mining
Alliance Mining Receives Drill Permit for its 100% Owned Packsack Gold Property in Bissett Gold Camp, Manitoba
Momentum Public Relations
Press Release: February 23 2018
Alliance Mining Corp. (TSXV: ALM) has received a drill permit for its upcoming drill program on its Packsack gold property. Alliance has an option to acquire 100% of the Red Rice Lake gold property, located in the centre of Bissett gold camp in Manitoba, Canada.
InvestmentPitch Media has produced a “video” which describes this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Alliance Mining” in the search box.
Cannot view this video? Visit:
http://www.investmentpitch.com/video/0_meee8fwb/Alliance-Mining-TSXVALM-received-drill-permit-for-its-upcoming-drill-program-on-its-Packsack-gold-property
The Red Rice Lake gold property claims are located within the Archean Rice Lake greenstone belt in southeastern Manitoba. This belt forms part of the Uchi sub province that includes the Red Lake and Pickle Crow belts in Northwestern Ontario.
The Packsack property hosts several gold-bearing veins within a conjugate fracture set adjacent to the Red Rice shear zone. The structural control on veining at the Packsack property is similar to that at the True North Mine, 4 km northeast, operated by Klondex Mines Ltd.
Previous exploration on the Packsack property has been focused on the Big Dome Vein, with a shaft to 525 feet (160 metres) and 2,867 feet (874 metres) of drifting and crosscutting on 4 levels down to 500 feet (152 metres), all completed between 1936 and 1940.
Christopher Anderson, President and CEO, stated: “We are looking forward to receiving drill results from this promising gold property. This property has never been explored below the shaft that was sunk in the 1930’s.”
The company is anticipating its drill program will commence in the near future and will be releasing a more comprehensive description of drill targets and locations shortly.
Alliance is also pleased to announce that it has retained consulting geologist William C. Hood, P.Geo to supervise the Packsack drilling program and to assist with expanding Alliance’s involvement in the Bissett gold camp. Mr. Hood has four decades of mineral exploration experience and has supervised multiple drill and exploration programs in the Bissett gold camp.
Alliance is actively seeking to expand its presence in the Bissett Gold camp through future property acquisitions and/or potential joint venture exploration partnerships with neighbouring companies.
For more information, please visit the company’s website www.alliancemining.com, contact Christopher R. Anderson, President and CEO, at 604-488-3900 or email ir@alliancemining.com.
- Published in Alliance Mining
Sirona Biochem Announces Development of Anti-Wrinkle Treatment and Update from J.P. Morgan Healthcare Conference
Momentum Public Relations
Press Release: January 31, 2018
Sirona Biochem Corp. (TSX VENTURE: SBM)(FRANKFURT: ZSB)(XETRA: ZSB) (the “Company”) announced today that the Company is developing an anti-wrinkle therapy.
The compound, LIP-01, was discovered to have a novel mechanism of action and will enter pre-clinical studies as a plumping/smoothing ingredient for aging skin. LIP-01 was tested on human skin cells called “normal human dermal fibroblasts” (NHDF). The treatment of the cells with the compound LIP-01 resulted in an up-regulation of gene expression leading to an activation of the signaling pathway of lipids. The presence of lipid vesicles in fibroblasts treated by compound LIP-01 showed cell differentiation of fibroblasts into lipo-fibroblasts. The increased synthesis of lipids in these cells leads to a plumping effect which is anticipated to fill wrinkles. Sirona’s scientists have also observed proliferation and preservation of fibroblasts when LIP-01 was added, important in countering the declining number of cells observed in aged skin. The Company and its consultants are building a development plan for this compound which includes a proof-of-concept clinical trial.
Loss of elasticity and degradation of fat tissue are two markers seen in aging skin, leading to the appearance of lines and wrinkles. Compounds that increase the number and volume of adipocytes (fat cells) can act as plumping, volumizing, and densifying skin agents, thereby reducing the visibility of wrinkle and potentially providing a more youthful look. The global anti-aging market is expected to grow to over $330 Billion USD by 2021 (Reuters, June 2017). Novel solutions are actively being sought out by the dermatology industry to address this.
“There was tremendous interest in these initial results when presented to companies on our recent trip to San Francisco during the J.P. Morgan Healthcare Conference,” said Dr. Howard Verrico, CEO. “The effects of compound LIP-01 on the skin cells suggest that this compound can contribute to improving the quality of dry skin and reduce the signs of aging. Our goal is to develop LIP-01 as a non-invasive treatment for wrinkles by a mechanism very different from dermal fillers and Botox®1.”
According to the American Society of Plastic Surgeons, using Botox® treatment for wrinkles is the most common cosmetic operation performed, generating 3 billion USD in revenue annually. However, Botox® is generally limited to use on the upper third of the face, specifically the frown lines between the eyebrows. Botox® also requires administration by a properly trained professional.
“Our scientists believe these two obstacles could be overcome with a topical therapy which could either replace or augment Botox® treatments. If clinically successful, LIP-01 could exceed Botox in market potential,” Verrico said.
In San Francisco, the Sirona team met with existing potential partners and established new ones in the cosmetic and dermatology industry to discuss both the skin-lightening portfolio and introduce LIP-01. The Company is pleased with the positive outcome of each meeting and is looking forward to continuing discussions during the American Academy of Dermatology Summit next month in San Diego. Several leading dermatologists who were excited by the data will be meeting with the Company to discuss next steps. Sirona Biochem is now in discussions with over a dozen companies regarding various aspects of the Company’s pipeline.
Sirona’s management also met with Obagi’s medical strategic development team to explore opportunities to commercialize its next-generation skin lighteners under a new agreement. The new skin lighteners are superior to its first-generation ones, having a simple synthetic pathway which results in a lower cost of goods. The first-generation compound, TFC-849, has proven difficult to manufacture in a commercially viable process. Obagi Medical under its new ownership will not be proceeding with the development of TFC-849. As a result, Sirona’s skin lightener library is no longer encumbered by restrictive clauses under the former licensing agreement and is now available for licensing world-wide.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
(1) BOTOX COSMETIC® is a registered trademark of Allergan Inc.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Sirona Biochem
Albert Mining Inc. Announces Results of Chapais Drill Program in Quebec
Momentum Public Relations
Press Release: January 24
Albert Mining Inc. (the “Company” or “Albert”) (TSX-V: AIIM), a mining exploration company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques in the mining sector, and Everton Resources Inc. (TSX-V: EVR) are pleased to announce results from their recent drilling campaign on the Chapais property which is situated immediately west of the Springer Copper Mine at Chapais, Quebec.
The drilling tested copper targets generated by Albert Mining’s proprietary CARDS 2D (Computer Aided Resources Detection System) system: The first hole (CHA-17-10) investigated Target A located at the hinge of a large fold which mimics the structural context at the nearby (3 km) Springer Mine. The two other holes (CHA-17-11 and CHA-17-12) were positioned on Target C located two kilometers to the northwest (Table 1). The core was logged by visual description and spot-checked for multi-elements by portable XRF. Selected core segments 0.5 to 1 meter in length were split and submitted to ALS Minerals for gold determination by Fire-Assay with AA finish, and for other elements by ICP-MS after partial digestion by aqua regia.
Table 1. Drill hole data.
Hole | Longitude | Latitude | Azm | Dip | Length |
id | (WGS 1984) | (?) | (?) | (m) | |
CHA-17-10 | 74? 52′ 40” W | 49? 48′ 05” N | 178 | -50 | 197 |
CHA-17-11 | 74? 54′ 07” W | 49? 48′ 40” N | 170 | -50 | 237 |
CHA-17-12 | 74? 54′ 07” W | 49? 48′ 40” N | 340 | -50 | 237 |
total | 671 |
The first hole intersected two one meter-thick (along core axis) mineralized zones assaying 1.61% Zn; and 1.74% Zn, and 0.59% Cu, respectively from 158.4 m to 159.4 m and 190.3 m to 191.3 m. These Zn – Cu values are associated with sulfidic and graphitic horizons in intensely folded fine-grained sediments of the Blondeau Fm. which locally shows a high zinc background (1000 – 2000 ppm). The first hole returned slightly anomalous gold values of 0.142 g/t Au over 1 m and 0.128 g/t Au over 0.5 m (along core axis), associated with semi massive sulfides. In the two last holes, pyroxenitewas observed to alternate with metasediments and volcanic flows of ultramafic affinities.
In addition to base metals, the Chapais property offers a strong potential for gold as exemplified by an historical reverse circulation drill hole that returned 6.29 g/t Au from a till sample (GM46158).
The scientific and technical content of this release was approved by Remi Charbonneau, P.Geo., a qualified person as defined by the National Instrument 43-101.
To quote Mr. Michel Fontaine, President & CEO of Albert Mining; “The encouraging results obtained from the short drilling campaign on the Chapais property will be followed by detailed IP geophysic surveying and additional till sampling”.
About Albert Mining Inc.
Albert is a junior mining exploration company with an extensive portfolio of gold, copper and diamond properties in Quebec. Albert also recently acquired all assets from DIAGNOS Inc.’s mining division, including the Computer Aided Resources Detection System (“CARDS”). Albert can count on a multidisciplinary team that includes professionals in geophysics, geology, Artificial Intelligence, and mathematics. The Company’s objective is to develop a new royalty stream by significantly enhancing and participating in the exploration success rate of mining.
For further information, please contact:
Michel Fontaine
President and CEO of Albert Mining Inc.
Telephone: 514-994-5843
Fax: 613-422-0773
Email: michel@albertmining.com
Website: www.albertmining.com
- Published in Albert Mining, Artificial Intelligence, Mining, Technology
Blue Moon Quoted on Pink Sheets and DTC Eligible; Positive Impact From US Corporate Tax Rate Reduction
Momentum Public Relations
Press Release: January 23
Blue Moon Zinc Corp. (TSXV: MOON; US OTC: BMOOF) (the “Company“) is pleased to report that the common shares of the Company are now quoted for trading in the United States on the OTC Pink Sheets under the trading symbol BMOOF. In addition, the Company’s common shares are eligible for delivery and depository services of The Depository Trust Company (the “DTC”) to facilitate electronic settlement of transfers of its common shares in the United States. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and greatly reduces transactional costs for participating stock brokerages. Investors can find the current Canadian financial disclosure of the Company on www.sedar.com.
Effective January 1, 2018, corporate tax rates in the United States were reduced from 35% to 21%, among other changes favoring US businesses. The Company’s Blue Moon zinc deposit is domiciled in the US and the corporate tax reduction is expected to be beneficial to the project and the Company’s Preliminary Economic Assessment (“PEA”) expected to be released in late Q1 2018.
Patrick McGrath, Chief Executive officer, stated, “The US quotation with DTC eligibility should enhance and simplify trading of our shares in the US. The Company’s Blue Moon Zinc deposit is based in the US and we believe being quoted and tradable in the US is complementary. We also welcome the recent US corporate tax reduction to 21% which we believe will improve the economics in the upcoming PEA”
About Blue Moon
The 100% owned Blue Moon polymetallic deposit has a Mineral Resource estimate of 3.7 million indicated tons with a grade of 8.3% zinc equivalence including approximately 377 million pounds of zinc and 4.1 million inferred tons with a grade of 7.8% zinc equivalence including approximately 395 million pounds of zinc with significant credits of copper, silver and gold. The resource is open at depth and along strike and historical metallurgical testing indicates excellent recovery and a clean zinc concentrate. A NI 43-101 report detailing the resource and summarizing metallurgical recoveries is available on the company’s website (www.bluemoonmining.com) and filed on SEDAR on November 13, 2017. The Company plans to advance the Blue Moon project through to feasibility, permitting and ultimately production.
Qualified Persons
Jack McClintock, P. Eng, a Director of the Company, is a qualified person as defined by NI 43-101, has reviewed the scientific and technical information that forms the basis for this press release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Resource estimates included in this news release are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions set forth in the relevant technical report and otherwise, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices for zinc, the results of future exploration, uncertainties related to the ability to obtain necessary permits, licenses and titles, changes in government policies regarding mining, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this press release, and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
The securities referenced in this news release have not and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
SOURCE Blue Moon Zinc Corp.
View original content: http://www.newswire.ca/en/releases/archive/January2018/23/c2491.html
Contact:
Patrick McGrath, CEO, 1-832-499-6009, pmcgrath@bluemoonmining.com; For additional information related to communications, media relations and investor relations please contact: Terry Bramhall, 1-604-833-6999, tbramhall@bluemoonmining.com
Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)
Momentum Public Relations
Press Release: January 16,2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.
According to Health Canada data1, the annual Canadian cannabis oil production for medical purposes was 22,766 kg between October 1st 2016 and September 30th 2017, and is growing continuously. In the third quarter of 2017, it grew 24% from Q2 (Apr-Jun) to Q3 (Jul-Sep)1. According to an Eight Capital analysis2, the cannabis oil market is expected to reach 1.5B$ in 2024.
The launch of this trial is the first step in Tetra’s plans to commercialize natural health products with its partners. The corporation will develop cannabis-based supplements for commercialization under the Natural Health Product regulations in Canada and in other countries where regulatory authorities have a recognized pathway for approval and commercialization of such products. The trial will eventually include formulations that will be registered as drugs under Health Canada’s TPD regulatory pathway. “Tetra Bio-Pharma Inc. seeks to become an important player in the retail market post legalization and this clinical trial is part of the sales and marketing strategy required to effectively penetrate the lucrative pharmacy and health stores retail markets,” states Bernard Fortier, CEO of Tetra.
Tetra’s vision is to develop an evidence-based approach, thereby allowing pharmacists to dispense these medicines to patients in need. Despite the growing popularity of cannabis oils, physicians and pharmacists across Canada are still hesitant to support the use of these products because of the lack of data supporting its medical use. Dr. Guy Chamberland, Chief Science Officer, commented: “This trial is part of Tetra’s corporate strategy to develop the science required to commercialize safe and efficacious cannabis oil products post-legalization and to create innovative oral drug formulations for the development of medicines in the management of pain, anxiety and the treatment of cancer.”
In that respect, Tetra’s scientific team is supporting the strategy by initiating a phase 1 clinical trial to characterize the safe use of these cannabis oil medicines in humans. Tetra has worked with Altasciences Clinical Research for the preparation of the Clinical Trial Application (CTA) for the conduct of a double-blind phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple daily doses of cannabis (Delta-9-tetrahydrocannabinol/Cannabidiol) oil capsules administered to healthy human volunteers. Health Canada issued a No Objection Letter for the conduct of the phase I clinical trial on January 12nd, 2018. Altasciences Clinical Research will be initiating the clinical trial activities in the coming weeks. The cannabis oil is manufactured by Tetra’s partner, Aphria Inc.
1: | Health Canada Market Data, [https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html] |
2: | Cannabis Sector, Eight Capital Estimates, July 2017 |
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
- Published in Medical Marijuana, Tetra Bio Pharma
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Momentum Public Relations
Press Release: August 23, 2017
VANCOUVER, BC–(Marketwired – August 23, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces an extension to the term of 8,850,770 common share purchase warrants (the “Warrants”) originally issued on March 6, 2014. The warrants were issued as part of a private placement. The expiry dates will be extended as follows:
March 6, 2014 | |
Number of Warrants: | 8,850,770 |
Original Expiry Date of Warrants: | March 6, 2017 |
New Expiry Date of Warrants: | November 30, 2017 |
Exercise Price of Warrants: | $0.25 |
All other terms of the Warrants will remain unchanged.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem, Technology
MOBI724 Global Solutions Inc. Announces its Intention to Apply to List its Shares on the TSXV
MOBI724 Global Solutions Inc. Announces its Intention to Apply to List its Shares on the TSXV
Momentum Public Relations
Press Release: July 25, 2017
MONTREAL, QUEBEC–(Marketwired – July 25, 2017) – MOBI724 Global Solutions Inc. (“MOBI724” or the “Company“) (CSE:MOS)(CSE:MOS.CN)(CNSX:MOS)(OTCQB:MOBIF), a fintech leader offering all in one fully integrated EMV payment, card link couponing and digital marketing solutions, announces its intention to apply immediatly to list its shares on the Toronto Stock Venture Exchange (TSXV).
“During our funding efforts in the first quarter of 2017, many of our investors requested that the Company list its shares on the TSXV. As announced last Friday, that the Company had filed and received a receipt for its final short form prospectus. The completion of this very important step shows that the Board of Directors and the management of the Company continue to take steps towards the eventual attainment of this milestone.” Says Marcel Vienneau, CEO MOBI724.
About MOBI724 Global Solutions
MOBI724, a leader in the fintech industry based in Montreal (Canada), offers a unique and fully integrated suite of payment & digital marketing solutions with a combined EMV Payment, Card Linked Offers, and Digital Marketing platform that works on any card and any mobile device. MOBI724’s solutions add value to all types of transactions benefiting banks, retailers and cardholders by leveraging available user and purchasing data to increase transaction volumes and spend. MOBI724 provides a turnkey solution to its clients to capture card transactions on any mobile device, at any point of sale or from any payment card. MOBI724 provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enable card associations, retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to any mobile device and allow its redemption at any point of sales.
Forward Looking Statements
Certain statements in this document, including those which express management’s expectations or estimations with regard to the Company’s future performance, constitute “forward-looking statements” as understood by applicable securities laws. Forward-looking statements are, of necessity, based on a certain number of estimates and hypotheses; while management considers these to be accurate at the time they are expressed, they are inherently subject to significant uncertainties and risks on the commercial, economic and competitive levels. We advise readers that these forward-looking statements are subject to risks, uncertainties, and other known and unknown factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied in these forward-looking statements. Investors are advised to not rely unduly on the forward-looking statements. This advisory applies to all forward-looking statements, whether expressed orally or in writing, attributed to the Company or to any individual expressing them in the name of the Company. Unless required by law, the Company is under no obligation to publicly update these forward-looking statements, whether to reflect new information, future events, or other circumstances.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
MOBI724 Global Solutions Inc.
Marcel Vienneau
1-514-394-5200 x 413
www.mobi724globalsolutions.com
- Published in Financial Technology, Mobi724 Global Solutions, Mobile Technology, News Home, Technology
Anfield Resources Inc. Announces $3.0 Million Private Placement
Anfield Resources Inc. Announces $3.0 Million Private Placement
Momentum Public Relations
Press Release: June 30, 2017
VANCOUVER, BC–(Marketwired – June 30, 2017) – Anfield Resources Inc. (TSX VENTURE: ARY) (FRANKFURT: 0AD)(OTCQB: ANLDF) (“Anfield” or “the Company”) is pleased to announce a fully-subscribed, non-brokered private placement for 50,000,000 Units at $0.06, for a total equity raise of $3.0 million. The Unit consists of one common share and a one share purchase warrant, with each warrant exercisable at $0.10 for a five-year term. Finders’ fees may be paid in certain instances.
Corey Dias, Anfield’s CEO, stated, “We are excited to announce the closing of this financing. These funds will allow us to both meet obligations related to Anfield’s current projects and seek out further acquisition opportunities. We remain very optimistic about the uranium market. With Kazatomprom establishing a marketing arm in Europe in order to position itself as a swing uranium seller, we would expect to see less pressure on the spot price going forward. In addition, the reduction in the number of tons of uranium to be sold per year by the US DOE should also have a positive effect on the uranium spot price. Finally, we believe that the continued pace in the building of nuclear reactors in places such as China, India and the UAE will spur a continuing rally in uranium prices and entice both current and new producers to either maintain or expand their production efforts. Anfield aims to be a supply contributor once the uranium price reflects this reality”.
The foregoing is subject to regulatory approval.
The proceeds of $3,000,000 will be used for project acquisition and development and general working capital purposes.
About Anfield
Anfield is an energy metals development and near-term production company that is committed to becoming a top-tier energy-related fuels supplier by creating value through sustainable, efficient growth in its energy metals assets. Anfield is a publicly-traded corporation listed on the TSX Venture Exchange (ARY-V), the OTCQB Marketplace (ANLDF) and the Frankfurt Stock Exchange (0AD). Anfield is focused on two production centers, as summarized below:
Arizona/Colorado/Utah – Shootaring Canyon Mill
The key asset in Anfield’s conventional uranium portfolio is the Shootaring Canyon Mill in Garfield County, Utah. The Shootaring Canyon Mill is strategically located within one of the historically most prolific uranium production areas in the United States, and is one of only three licensed uranium mills in the United States.
Anfield’s uranium assets consist of conventional mining claims and state leases in southeastern Utah, Colorado and Arizona, targeting areas where past uranium mining or prospecting occurred. Anfield’s conventional uranium assets include the Velvet-Wood Project, the Frank M Uranium Project, as well as the Findlay Tank breccia pipe. All conventional uranium assets are situated within a 125-mile radius of the Shootaring Mill.
Wyoming Properties – Irigaray ISR Processing Plant (Resin Processing Agreement)
Anfield’s ISR mining projects are located in the Black Hills, Powder River Basin, Great Divide Basin, Laramie Basin, Shirley Basin and Wind River Basin areas in Wyoming, and comprise 2,667 federal mining claims, 56 Wyoming State leases and 15 private leases acquired from Uranium One in September 2016.
Anfield has agreed to enter into a Resin Processing Agreement with Uranium One wherein Anfield would process up to 500,000 pounds per annum of its mined material at Uranium One’s Irigaray Central Processing Plant in Wyoming.
On behalf of the Board of Directors
ANFIELD RESOURCES INC.
Corey Dias,
Chief Executive Officer
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS “FORWARD-LOOKING STATEMENTS”. STATEMENTS IN THIS NEWS RELEASE THAT ARE NOT PURELY HISTORICAL ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE.
EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS “ESTIMATE,” “ANTICIPATE,” “BELIEVE,” “PLAN” OR “EXPECT” OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH MINERAL EXPLORATION AND FUNDING AS WELL AS THE RISKS SHOWN IN THE COMPANY’S MOST RECENT ANNUAL AND QUARTERLY REPORTS AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY’S ABILITY AND LEVEL OF SUPPORT FOR ITS EXPLORATION AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY’S EXPLORATION EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY’S PERIODIC REPORTS FILED FROM TIME-TO-TIME.
THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKES FULL RESPONSIBILITY FOR ITS CONTENTS. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
Contact:
Anfield Resources, Inc.
Clive Mostert
Corporate Communications
780-920-5044
info@anfieldresources.com
www.anfieldresources.com
- Published in Anfield Resources, Mining, News Home